Yemaachi Presents Findings on Mutation Profiles of Ghanaian Women with Breast Cancer at AORTIC 2023; Announces Formation of African Clinical Cancer Research Network
Results presented in collaboration with Paemka Research Group at the University of Ghana represent largest sequencing study of its kind conducted entirely in Africa to date; Company’s cancer network will advance and scale precision oncology research and collaborations across the continent
Supported by £3.1 million from the Wellcome Trust, the newly-created WWW Consortium links three leading studies in West Africa (Yemaachi Biotech Heritage Study), the West Indies (Windfall Study in Kingston, Jamaica), and West London (the Legacy Study), each tracking how both the virus and our immunity has evolved against COVID-19.
As one of Ghana’s only labs equipped for molecular analysis, Bediako’s team have tasked themselves with collecting data they believe will advance the development of medicine for cancer patients throughout the continent and diaspora
Yemaachi, Africa’s Cancer Research Company, Raises Seed Round To Diversify Genomic Datasets & Advance Precision Oncology Globally
Yemaachi Biotech announced today the close of a $3 million seed round to advance its mission of diversifying precision oncology globally. V8 Capital led the round, with LifeLine Family Heritage Fund, Y Combinator, Tencent, LoftyInc Capital, VestedWorld, V Square Capital and Ethan Perlstein also participating.
GenomeWeb covers Yemaachi’s launch of its Sheba HPV Test, a convenient discreet way for women to screen themselves for HPV and assess their risk for cervical cancer.
Yemaachi Biotech’s Heritage Study is the first of its kind to compare immune responses to the same vaccine in both African and European populations, and could provide important insights into how vaccines can be optimally designed for African people
Yemaachi Launches Sheba HPV Test for screening of high risk HPV variants that cause cervical cancer￼
Yemaachi marks cervical cancer awareness month with the launch of the Sheba HPV Test, a cervical cancer screening tool that features at-home sampling and high risk HPV DNA detection.
GenomeWeb covers Yemaachi’s collaboration with cancer liquid biopsy firm Lucence to document and characterize the genomics of breast cancer in women of African descent.
Lucence and Yemaachi Launch the AMBER Study to Detect and Characterize Genomic Alterations in Breast Cancer in Women in Africa and Expand Liquid Biopsy Access
PALO ALTO, Calif. & ACCRA, Ghana–(BUSINESS WIRE)–Lucence, a precision oncology company using liquid biopsy to bring clarity to cancer care, and Yemaachi Biotech, a cancer research company based in Accra, Ghana, announced today that they are collaborating on a study to better characterize and understand the genomics of breast cancer in women of African descent.